ERBB2 and breast cancer: Although several studies in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy and single HER2-blockade have demonstrated an association between higher TILs and improved chances of pCR and a more favorable prognosis, results have been inconsistent in trials of dual HER2-blockade20–24,26,28–31.